Sign in

CIK 0001427570

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

Vyome Holdings, Inc

Sign in to watch
Ticker
HIND
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 949-429-6680
Business address
1001 CALLE AMANECER, SAN CLEMENTE, CA, 92673
Former names
ReShape Lifesciences Inc., OBALON THERAPEUTICS INC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 1 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2019-01-02 Drake Neil VP Research and Development Grant or award · Stock Option (Right to Buy) +35,000 35,000
2018-08-23 Drake Neil VP Research and Development Grant or award +13,736 $1.82 $25K 61,267
2018-05-15 Drake Neil VP Research and Development Grant or award +17,938 17,938
2018-04-30 Drake Neil VP Research and Development Grant or award +2,743 $3.27 $9K 29,593
2018-03-15 Drake Neil VP Research and Development Purchase +5,000 $3.96 $20K 26,850
2018-02-02 Drake Neil VP Research and Development Option exercise +229 $1.31 $300 8,153
2018-02-02 Drake Neil VP Research and Development Option exercise +5,746 $1.83 $11K 13,899
2018-02-02 Drake Neil VP Research and Development Option exercise +3,641 $0.76 $3K 17,540
2018-02-02 Drake Neil VP Research and Development Option exercise +4,310 $1.77 $8K 21,850
2018-02-02 Drake Neil VP Research and Development Option exercise · Employee Stock Option (right to buy) −229 0
2018-02-02 Drake Neil VP Research and Development Option exercise · Employee Stock Option (right to buy) −5,746 0
2018-02-02 Drake Neil VP Research and Development Option exercise · Employee Stock Option (right to buy) −3,641 1,083
2018-02-02 Drake Neil VP Research and Development Option exercise · Employee Stock Option (right to buy) −4,310 6,034
2018-01-02 Drake Neil VP Research and Development Grant or award · Stock Option (Right to Buy) +35,000 35,000
2017-10-31 Drake Neil VP Research and Development Grant or award +1,743 $7.17 $12K 7,924
2017-04-30 Drake Neil Director Grant or award +1,661 $9.03 $15K 6,181

Page 1 of 1 · 16 trades